(July 6, 2020, 2:05 PM EDT) -- NEW YORK — A point-of-care diagnostics company and certain of its senior executives were hit with a second securities class action on July 3 in New York federal court, alleging that the defendants misrepresented the accuracy of the company’s antibody test used to determine current or past exposure to COVID-19 in violation of federal securities law (Anthony Bailey v. Chembio Diagnostics Inc., et al., No. 20-2961, E.D. N.Y.)....